Sanofi Stock News

Sanofi (SNY) posts first-quarter 2024 results and maintains the earnings growth guidance for the year.

Sanofi (NASDAQ:SNY ) Q1 2024 Earnings Conference Call April 25, 2024 8:30 AM ET Company Participants Paul Hudson - Chief Executive Officer François-Xavier Roger - Chief Financial Officer Houman Ashra

Sanofi backed its full-year earnings guidance after it reported first-quarter profit ahead of consensus, with sales growth driven by continued strength in anti-inflammatory drug Dupixent and its new d

Sanofi's said on Thursday first-quarter operating income declined 14.7% as unfavourable currency effects and cheap competition to multiple sclerosis drug Aubagio outweighed rising sales of anti-inflam

Let's look at five biotech/drug companies, MRK, SNY, BMY, GILD and ABBV, slated to release their first quarter 2024 earnings results this week.

Sanofi's (SNY) BTK inhibitor, rilzabrutinib, demonstrates durable platelet response in the phase III LUNA 3 study in adult patients with immune thrombocytopenia.

The Federal Trade Commission is working to accelerate its inquiry into the prescription-drug middlemen known as pharmacy-benefit managers, while also expanding its scrutiny of drug patents that can ke

A couple of big-picture trends in biotech could add up to a nice investment opportunity. First, corporate buyouts are back in style.

The Mag Seven stocks have powered gains in the U.S. market. Now, the hunt is on for an equivalent group of outperformers elsewhere.

Sanofi (NASDAQ: SNY ) layoffs are in the news Monday after the therapeutic solutions company announced changes to how it will handle research and development going forward. Sanofi wants to focus mor

A Type 2 diabetes medication called lixisenatide appeared to slow the progression of Parkinson's disease symptoms in a small, mid-stage trial funded by the French Ministry of Health and others, the Ne

Sanofi has reached an agreement in principle to settle 4,000 lawsuits linking the discontinued heartburn drug Zantac to cancer, the company said on Wednesday.

Sanofi has underperformed the U.S. stock market lately but now offers one of the smartest growth-at-a-reasonable-price setups in Big Pharma. Sanofi is best known for its patented drug Dupixent and num

While the U.S. is the best block in the neighborhood, sometimes, the area could get a little crowded, which then may offer an opportunity for global growth stocks. No one's saying to avoid American se

Sanofi (SNY) Leerink Partners Global Biopharma Conference (Transcript)